-
公开(公告)号：US20170174688A1
公开(公告)日：2017-06-22
申请号：US14972482
申请日：2015-12-17
Applicant: AbbVie Inc.
Inventor： Yujia Dai , William McClellan , Mike Michaelides , Ramzi Sweis , Noel Wilson , Justin Dietrich
IPC: C07D473/34 , C12Q1/48 , C07D519/00
CPC classification number: C07D473/34 , C07D519/00 , C12Q1/48 , G01N2333/91017 , G01N2500/04
Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
2.发明授权公开(公告)号：US09656955B2
公开(公告)日：2017-05-23
申请号：US14216222
申请日：2014-03-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC classification number: C07D207/48 , A61K31/4025 , A61K31/4178 , A61K31/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
3.发明申请PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权吡咯烷衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20140275087A1
公开(公告)日：2014-09-18
申请号：US14216222
申请日：2014-03-17
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: C07D207/48 , C07D403/14 , C07D401/14 , C07D403/12 , C07D401/12
CPC classification number: C07D207/48 , A61K31/4025 , A61K31/4178 , A61K31/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
Abstract translation: 本发明涉及式（I）的吡咯烷衍生物或其生理上耐受的盐。 本发明涉及包含这种吡咯烷衍生物的药物组合物以及这种吡咯烷衍生物用于治疗目的的用途。 吡咯烷衍生物是GlyT1抑制剂。
-
公开(公告)号：US10273238B2
公开(公告)日：2019-04-30
申请号：US15852179
申请日：2017-12-22
Applicant: AbbVie Inc.
Inventor： Eric C. Breinlinger , Andrew Burchat , Justin Dietrich , Michael Friedman , David Ihle , David Kinsman , Kelly Mullen , Augustine Osuma , Anil Vasudevan , Noel S. Wilson
IPC: C07D487/04 , C07D519/00 , C07D498/04
Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
-
公开(公告)号：US20160304526A1
公开(公告)日：2016-10-20
申请号：US15130323
申请日：2016-04-15
Applicant: AbbVie Inc.
Inventor： Eric Breinlinger , Andrew Burchat , Justin Dietrich , Michael Friedman , David Ihle , David Kinsman , Kelly Mullen , Augustine Osuma , Anil Vasudevan , Noel Wilson
IPC: C07D487/04 , C07D498/04 , C07D519/00
CPC classification number: C07D487/04 , C07D498/04 , C07D519/00
Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
Abstract translation: 药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本公开的化合物可用于治疗免疫学和肿瘤学病症。
-
Patent Agency Ranking
公开(公告)号：US20160304517A1
公开(公告)日：2016-10-20
申请号：US15130362
申请日：2016-04-15
Applicant: AbbVie Inc.
Inventor： Eric C. Breinlinger , Phil B. Cox , Jerome Daanen , Justin Dietrich , Stevan Djuric , Amanda W. Dombrowski , Kristine E. Frank , Michael M. Friedman , Arthur Gomtsyan , Huan-Qui Li , Kenton Longenecker , Augustine Osuma , Ann Marie Rowley , Robert Schmidt , Anil Vasudevan , Noel Wilson
IPC: C07D471/04 , C07D491/147 , C07D491/22 , C07D498/04 , C07D471/18 , C07D471/14 , C07D498/22 , C07D498/14 , C07D498/20 , C07D487/04 , C07D519/00
CPC classification number: C07D471/04 , C07D471/14 , C07D471/18 , C07D487/04 , C07D491/147 , C07D491/22 , C07D498/04 , C07D498/14 , C07D498/18 , C07D498/20 , C07D498/22 , C07D519/00
Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
Abstract translation: 本发明提供三环杂环化合物，药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。
-
公开(公告)号：US09879016B2
公开(公告)日：2018-01-30
申请号：US15130323
申请日：2016-04-15
Applicant: AbbVie Inc.
Inventor： Eric Breinlinger , Andrew Burchat , Justin Dietrich , Michael Friedman , David Ihle , David Kinsman , Kelly Mullen , Augustine Osuma , Anil Vasudevan , Noel Wilson
IPC: C07D487/04 , C07D498/04 , C07D519/00
CPC classification number: C07D487/04 , C07D498/04 , C07D519/00
Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
-
8.发明授权公开(公告)号：US09650334B2
公开(公告)日：2017-05-16
申请号：US14215533
申请日：2014-03-17
Applicant: AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: A61K31/4025 , A61K31/44 , A61K31/4178 , C07D207/09 , C07D403/12 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D487/04
CPC classification number: C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
9.发明申请公开(公告)号：US20140275086A1
公开(公告)日：2014-09-18
申请号：US14215533
申请日：2014-03-17
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying X. Wang , Hongyu H. Zhao , Huan-Qiu Li , Jason T. Brewer , Irini Zanze , Justin Dietrich , Anil Vasudevan , Stevan W. Djuric , Yanbin Lao , Charles W. Hutchins
IPC: C07D207/09 , C07D401/12 , C07D207/48 , C07D401/14 , C07D403/14 , C07D487/04 , C07D487/10 , C07D417/14 , C07D409/14 , C07D495/04 , C07D471/04 , C07D403/12 , C07D405/14
CPC classification number: C07D207/09 , A61K31/4025 , A61K31/44 , C07D207/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/10 , C07D495/04
Abstract: The present invention relates to pyrrolidine derivatives of the formula (I), or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such pyrrolidine derivatives, and the use of such pyrrolidine derivatives for therapeutic purposes. The pyrrolidine derivatives are GlyT1 inhibitors.
-
公开(公告)号：US09932340B2
公开(公告)日：2018-04-03
申请号：US14972482
申请日：2015-12-17
Applicant: AbbVie Inc.
Inventor： Yujia Dai , William McClellan , Mike Michaelides , Ramzi Sweis , Noel Wilson , Justin Dietrich
IPC: C07D473/34 , C07D519/00 , C12Q1/48
CPC classification number: C07D473/34 , C07D519/00 , C12Q1/48 , G01N2333/91017 , G01N2500/04
Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.026 seconds)
